
The civil rights leader Rev. Jesse Jackson has been hospitalized, the Rainbow PUSH Coalition announced Wednesday evening.
Jackson, 84, has been admitted to the hospital and is under observation for progressive supranuclear palsy, a neurodegenerative condition, which he has been managing for a decade, the organization said in a statement.
"The family appreciates all prayers at this time," the group said.
Jackson was originally diagnosed with Parkinson's disease, however his PSP condition was confirmed in April, the organization said.
PSP is a rare neurological disorder which affects body movements, walking and balance, and eye movements, according to the National Institutes of Health. It is caused by damage to nerve cells in parts of the brain.
Jackson, a protege to the Rev. Martin Luther King Jr. who rose to prominence as one of the nation's foremost civil rights leaders and twice ran for U.S. president, stepped down in 2023 from the leadership of the Rainbow PUSH Coalition, which he founded.
LATEST POSTS
- 1
Southern Californians, your health insurance costs could rise in 2026 - 2
US FDA approves Kura-Kyowa's blood cancer therapy - 3
Exploring the School Application Cycle: Understudy Bits of knowledge - 4
German petrol stations hike prices as once-a-day rule takes effect - 5
Christopher Nolan's 'The Odyssey' trailer: See Anne Hathaway, Matt Damon and Tom Holland in 1st look at movie
I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
BHP liable for 2015 Brazil mine disaster: UK court
Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
MEPs urge Commission leaders to stop Russia from returning to the Venice Biennale
Somaliland denies trading recognition with Israel for accepting Gazans
$30K Disability Scam Implodes After Surf Trip in Mexico
IDF kills senior PIJ Gaza City Brigade cmdr. who infiltrated Kibbutz Nahal Oz on Oct. 7
Spanish woman, 25, dies by legal euthanasia in case that drew national spotlight
Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers













